Fig. 1: Comparative molecular characterization of HER2-zero (n = 31) and HER2-low (n = 64) TNBC tumors.
From: Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer
a The OncoPrint view of the top eight mutated genes. Genes are sorted by the frequency of variants in the overall study population. The percentages listed show the frequency of alterations in HER2-zero and HER2-low, respectively. b TMB levels in HER2-zero and HER2-low TNBC tumors. TMB is represented as log10 of mutations per Mb sequenced. HER2-zero TNBC is shown in purple and HER2-low in turquoise. The Wilcoxon rank-sum test was used to test statistical differences: *P < 0.05. c Percentage of ERBB2 gene copy number category for each cohort. Gain: >2 copies, diploid: 2 copies, and loss of heterozygosity: =1 copy. HER2-zero TNBC is shown in purple and HER2-low in turquoise. The Chi-square test was used to test statistical differences. d Boxplots showing the protein levels of HER2 and phosphorylated HER2 (pHER2-Y1248) in HER2-zero and HER2-low TNBC tumors. HER2-zero TNBC is shown in purple and HER2-low in turquoise. Student’s t-test and Wilcoxon rank-sum test were used respectively to test statistical differences: *P < 0.05. TNBC triple-negative breast cancer, TMB tumor mutational burden, LOH loss of heterozygosity.
